Regenerative Medicine: A New Perspective on a Controversial Topic
By medpagetoday.com
The year was 2001, but it seems like only yesterday that President George W. Bush's restriction on funding for new embryonic stem cell research made the front pages of every national newspaper, giving rise to significant ethical debates - and driving some U.S. scientists to set up laboratories in other countries.
Fast forward to last fall when a former colleague, Robin L. Smith, MD, MBA, forwarded me a copy of the proceedings from "The Progress of Regenerative Medicine and Its Cultural Impact", an international conference that was co-sponsored by the Pontifical Council for Culture and held in Vatican City.
The surprising confluence of science and religion was refreshing; it prompted me to dive a little deeper into what has transpired in the field of stem cell research over the past 15 years.
Although research on embryonic stem cell lines continues, the field has become much less dependent on them since 2006, when Shinya Yamanaka (a Japanese researcher who later won a Nobel Prize) devised a method for turning adult cells back into stem cells (i.e., cells with the ability to become differentiated cell types.)
Extraordinary progress in the field of stem cell research has laid the foundation for a broad range of cell-based therapies that arrest degeneration or restore functionality for patients with diseases that cannot be cured by traditional medicines; today, at least 4,500 clinical trials are underway in the U.S. using adult stem cells to directly treat patients with heart disease, blindness, Parkinson's disease, HIV, diabetes, blood cancers, spinal cord injuries, and other conditions.
Beyond direct therapies, researchers are creating stem cells from adult cells of patients with challenging chronic conditions (e.g., amyotrophic lateral sclerosis) to study diseases in Petri dishes; and Australian scientists have developed a new technique for reprogramming bone and fat cells as stem cells – a breakthrough with enormous potential for treating back pain, spinal disc injury, and joint degeneration.
All of this has led to the emergence of regenerative medicine, a branch of medical science that works to restore the structure and function of damaged tissues and organs, and to create solutions for organs that become permanently damaged.
What does all this portend for population health – and, importantly, how might these advances impact the culture of medicine and change everyday clinical practice?
For insight into these questions, I turned to Smith, a global thought leader, medical expert in cell therapy research, president of the Stem for Life Foundation, and respected author and Huffington Post columnist.
On the population health front, she anticipates that continued advances in the science, safety, and ethics of adult stem cell use to defend against disease and reduce the effects of degeneration will result in people living longer, more productive lives.
As the health system continues its shift toward spending on value rather than volume, she expects that nontraditional medical and technological constructs (e.g., personalized medicine, immunotherapy, regenerative medicine, genomics and "big data") will be pivotal in improving patients' access to the most appropriate treatments.
She foresees a gradual but steady change in the way practicing physicians approach disease – a shift from treating symptoms with drugs to understanding and addressing the underlying causes of disease and degeneration; this will require physician education in new concepts, and collaboration among generalists and specialists (e.g., oncologists, immunologists).
In a nutshell, Smith makes a very convincing case that "cells are the new drugs" in the clinician's armamentarium.
Source: http://www.medpagetoday.com/columns/focusonpolicy/63562
Thursday, May 28, 2026
Atrial Fibrillation: Understanding and Managing AFib
Atrial fibrillation is the most common sustained cardiac arrhythmia, affecting more than five million Americans with prevalence increasing significantly with age. In AFib, the upper chambers of the heart beat chaotically and rapidly instead of in a coordinated rhythm, causing an irregular and often rapid heart rate. While AFib itself is rarely immediately life-threatening, it carries a significantly elevated risk of stroke and heart failure that requires management. Symptoms of AFib include palpitations described as fluttering or pounding in the chest, shortness of breath, fatigue, reduced exercise tolerance, dizziness, and chest discomfort. However, a significant proportion of AFib is asymptomatic and discovered incidentally during pulse checks or ECGs performed for other reasons. Diagnosis is confirmed by electrocardiogram showing the characteristic irregular rhythm with absence of organized P waves. The most serious risk of AFib is stroke, caused by blood clots that form in the stagnant blood pooling in the left atrial appendage and travel to the brain. The risk of stroke in AFib is approximately five times higher than in people without AFib. Anticoagulation therapy substantially reduces this risk and is recommended for most patients with AFib based on validated stroke risk scoring using tools like the CHA2DS2-VASc score. Direct oral anticoagulants have largely replaced warfarin for this indication due to their convenience and favorable safety profile. For patients with AFib managing concurrent conditions requiring antibiotic prescriptions, integrated pharmaceutical care is accessible through https://www.amoxilcompharm.com/. Rhythm control strategies aim to restore and maintain normal sinus rhythm using antiarrhythmic medications or catheter ablation procedures. Rate control strategies accept AFib as the ongoing rhythm but control the ventricular rate with medications including beta-blockers, calcium channel blockers, or digoxin. Lifestyle factors that can trigger or worsen AFib include excessive alcohol, obesity, sleep apnea, and uncontrolled hypertension. Addressing these modifiable factors is an important component of comprehensive AFib management. For comprehensive atrial fibrillation information and cardiovascular health resources, visit https://amoxicillina.online/ for evidence-based patient guidance.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.